Literature DB >> 9617896

Mobilization of peripheral blood progenitor cells by Betafectin PGG-Glucan alone and in combination with granulocyte colony-stimulating factor.

M L Patchen1, J Liang, T Vaudrain, T Martin, D Melican, S Zhong, M Stewart, P J Quesenberry.   

Abstract

Betafectin PGG-Glucan, a novel beta-(1,6) branched beta-(1,3) glucan purified from the cell walls of Saccharomyces cerevisiae, has been shown to synergize with myeloid growth factors in vitro and to enhance hematopoietic recovery in myelosuppressed mice and primates. Here we report that PGG-Glucan is also capable of mobilizing peripheral blood progenitor cells (PBPC). PGG-Glucan (0.5 mg/kg to 16 mg/kg) was administered intravenously to C3H/HeN male mice and blood collected at times ranging from 30 min to seven days after injection. Based on granulocyte-macrophage colony-forming cell (GM-CFC) levels, peak mobilization occurred 30 min after a 2 mg/kg PGG-Glucan dose. At this time GM-CFC numbers in PGG-Glucan-treated mice were approximately fourfold greater than in saline-treated control mice. A second, smaller wave of GM-CFC mobilization (approximately twofold increase) also occurred on days 4 and 5 after PGG-Glucan treatment. Mobilization was not associated with the induction of alpha-chemokines, which have recently been reported to induce rapid progenitor cell mobilization. Competitive repopulation experiments performed in irradiated female C3H/HeN mice revealed that, at three months after transplantation, more male DNA was present in bone marrow, splenic, and thymic tissues from animals transplanted with cells obtained from mice 30 min after a 2 mg/kg PGG-Glucan dose than in tissues from animals transplanted with cells obtained from saline-treated mice. Additional experiments evaluated the mobilization effects of PGG-Glucan (2 mg/kg) administered to mice which had been pretreated for three consecutive days with G-CSF (125 microg/kg/day). When blood was collected 30 min after PGG-Glucan treatment, the number of GM-CFC mobilized in combination-treated mice was additive between the number mobilized in mice treated with G-CSF alone and the number mobilized in mice treated with PGG-Glucan alone. These studies demonstrate that: A) PGG-Glucan can rapidly mobilize PBPC; B) the kinetic pattern of PGG-Glucan-induced mobilization is different from that of the CSFs; C) the reconstitutional potential of PGG-Glucan mobilized cells is greater than that of steady-state PBPC, and D) PGG-Glucan can enhance G-CSF-mediated PBPC mobilization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9617896     DOI: 10.1002/stem.160208

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  11 in total

Review 1.  Concise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilization.

Authors:  Jonathan Hoggatt; Jennifer M Speth; Louis M Pelus
Journal:  Stem Cells       Date:  2013-12       Impact factor: 6.277

2.  Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence.

Authors:  E A Sweeney; G V Priestley; B Nakamoto; R G Collins; A L Beaudet; T Papayannopoulou
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Improved antimicrobial host defense in mice following poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose glucan treatment by a gender-dependent immune mechanism.

Authors:  Courtni T Newsome; Estefany Flores; Alfred Ayala; Stephen Gregory; Jonathan S Reichner
Journal:  Clin Vaccine Immunol       Date:  2011-10-05

4.  Enhancement of umbilical cord blood cell hematopoiesis by maitake beta-glucan is mediated by granulocyte colony-stimulating factor production.

Authors:  Hong Lin; Sandy W Y Cheung; Mirjana Nesin; Barrie R Cassileth; Susanna Cunningham-Rundles
Journal:  Clin Vaccine Immunol       Date:  2006-11-08

5.  Maitake beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse.

Authors:  Hong Lin; Elisa De Stanchina; Xi Kathy Zhou; Yuhong She; Danthanh Hoang; Sandy Wy Cheung; Barrie Cassileth; Susanna Cunningham-Rundles
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-14

Review 6.  Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy.

Authors:  Jingjing Liu; Lacey Gunn; Richard Hansen; Jun Yan
Journal:  Exp Mol Pathol       Date:  2009-01-21       Impact factor: 3.362

7.  Comparison of the efficacy of hematopoietic stem cell mobilization regimens: a systematic review and network meta-analysis of preclinical studies.

Authors:  Chengxin Luo; Li Wang; Guixian Wu; Xiangtao Huang; Yali Zhang; Yanni Ma; Mingling Xie; Yanni Sun; Yarui Huang; Zhen Huang; Qiuyue Song; Hui Li; Yu Hou; Xi Li; Shuangnian Xu; Jieping Chen
Journal:  Stem Cell Res Ther       Date:  2021-05-29       Impact factor: 6.832

8.  A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy.

Authors:  Alan B Weitberg
Journal:  J Exp Clin Cancer Res       Date:  2008-09-19

Review 9.  Modulation of animal and human hematopoiesis by β-glucans: a review.

Authors:  Michal Hofer; Milan Pospíšil
Journal:  Molecules       Date:  2011-09-15       Impact factor: 4.411

Review 10.  Mobilized peripheral blood: an updated perspective.

Authors:  Darja Karpova; Michael P Rettig; John F DiPersio
Journal:  F1000Res       Date:  2019-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.